India · Delayed Price · Currency is INR Kabra Drugs Statistics
Total Valuation
Kabra Drugs has a market cap or net worth of INR 789.23 million. The enterprise value is 676.94 million.
| Market Cap | 789.23M |
| Enterprise Value | 676.94M |
Important Dates
The next estimated earnings date is Friday, February 13, 2026.
| Earnings Date | Feb 13, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Kabra Drugs has 23.71 million shares outstanding. The number of shares has increased by 617.12% in one year.
| Current Share Class | 23.71M |
| Shares Outstanding | 23.71M |
| Shares Change (YoY) | +617.12% |
| Shares Change (QoQ) | +0.23% |
| Owned by Insiders (%) | 22.52% |
| Owned by Institutions (%) | 0.24% |
| Float | 18.37M |
Valuation Ratios
The trailing PE ratio is 53.65.
| PE Ratio | 53.65 |
| Forward PE | n/a |
| PS Ratio | 2.93 |
| PB Ratio | 3.04 |
| P/TBV Ratio | 3.04 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 90.37, with an EV/FCF ratio of -5.91.
| EV / Earnings | 56.70 |
| EV / Sales | 2.52 |
| EV / EBITDA | 90.37 |
| EV / EBIT | 93.11 |
| EV / FCF | -5.91 |
Financial Position
The company has a current ratio of 1.87, with a Debt / Equity ratio of 0.02.
| Current Ratio | 1.87 |
| Quick Ratio | 1.13 |
| Debt / Equity | 0.02 |
| Debt / EBITDA | 0.63 |
| Debt / FCF | -0.04 |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is 8.16% and return on invested capital (ROIC) is 5.99%.
| Return on Equity (ROE) | 8.16% |
| Return on Assets (ROA) | 1.53% |
| Return on Invested Capital (ROIC) | 5.99% |
| Return on Capital Employed (ROCE) | 2.79% |
| Weighted Average Cost of Capital (WACC) | 2.24% |
| Revenue Per Employee | 8.68M |
| Profits Per Employee | 385,097 |
| Employee Count | 31 |
| Asset Turnover | 0.91 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, Kabra Drugs has paid 3.68 million in taxes.
| Income Tax | 3.68M |
| Effective Tax Rate | 23.57% |
Stock Price Statistics
The stock price has increased by +215.25% in the last 52 weeks. The beta is -0.36, so Kabra Drugs's price volatility has been lower than the market average.
| Beta (5Y) | -0.36 |
| 52-Week Price Change | +215.25% |
| 50-Day Moving Average | 29.06 |
| 200-Day Moving Average | 20.37 |
| Relative Strength Index (RSI) | 68.81 |
| Average Volume (20 Days) | 127,546 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Kabra Drugs had revenue of INR 269.14 million and earned 11.94 million in profits. Earnings per share was 0.62.
| Revenue | 269.14M |
| Gross Profit | 36.40M |
| Operating Income | 7.27M |
| Pretax Income | 15.62M |
| Net Income | 11.94M |
| EBITDA | 7.49M |
| EBIT | 7.27M |
| Earnings Per Share (EPS) | 0.62 |
Balance Sheet
The company has 116.99 million in cash and 4.69 million in debt, with a net cash position of 112.29 million or 4.74 per share.
| Cash & Cash Equivalents | 116.99M |
| Total Debt | 4.69M |
| Net Cash | 112.29M |
| Net Cash Per Share | 4.74 |
| Equity (Book Value) | 259.92M |
| Book Value Per Share | 10.90 |
| Working Capital | 247.36M |
Cash Flow
In the last 12 months, operating cash flow was -107.57 million and capital expenditures -6.91 million, giving a free cash flow of -114.47 million.
| Operating Cash Flow | -107.57M |
| Capital Expenditures | -6.91M |
| Free Cash Flow | -114.47M |
| FCF Per Share | -4.83 |
Margins
Gross margin is 13.52%, with operating and profit margins of 2.70% and 4.44%.
| Gross Margin | 13.52% |
| Operating Margin | 2.70% |
| Pretax Margin | 5.80% |
| Profit Margin | 4.44% |
| EBITDA Margin | 2.78% |
| EBIT Margin | 2.70% |
| FCF Margin | n/a |
Dividends & Yields
Kabra Drugs does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -617.12% |
| Shareholder Yield | -617.12% |
| Earnings Yield | 1.51% |
| FCF Yield | -14.50% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Kabra Drugs has an Altman Z-Score of 1.9 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.9 |
| Piotroski F-Score | 2 |